SOL-GEL TECHN. IS-10 (F:4SG) — Market Cap & Net Worth
Market Cap & Net Worth: SOL-GEL TECHN. IS-10 (4SG)
SOL-GEL TECHN. IS-10 (F:4SG) has a market capitalization of $188.25 Million (€161.02 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #16869 globally and #1588 in its home market, demonstrating a 6.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SOL-GEL TECHN. IS-10's stock price €65.50 by its total outstanding shares 3273999 (3.27 Million). Also see SOL-GEL TECHN. IS-10 assets under control for a full breakdown of the balance sheet.
SOL-GEL TECHN. IS-10 Market Cap History: 2019 to 2026
SOL-GEL TECHN. IS-10's market capitalization history from 2019 to 2026. Data shows growth from $43.25 Million to $250.71 Million (32.11% CAGR). Also see cash flow conversion of SOL-GEL TECHN. IS-10 for how efficiently the company converts equity into cash flow.
SOL-GEL TECHN. IS-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SOL-GEL TECHN. IS-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 4SG share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.46x
SOL-GEL TECHN. IS-10's market cap is 7.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $22.01 Million | $31.27 Million | $3.22 Million | 0.70x | 6.83x |
| 2022 | $14.70 Million | $3.88 Million | -$14.92 Million | 3.79x | N/A |
| 2023 | $4.13 Million | $1.55 Million | -$27.24 Million | 2.66x | N/A |
| 2024 | $3.83 Million | $11.54 Million | -$10.58 Million | 0.33x | N/A |
| 2025 | $144.69 Million | $19.39 Million | -$6.13 Million | 7.46x | N/A |
Competitor Companies of 4SG by Market Capitalization
Companies near SOL-GEL TECHN. IS-10 in the global market cap rankings as of September 19, 2026. Review SOL-GEL TECHN. IS-10 tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SOL-GEL TECHN. IS-10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
SOL-GEL TECHN. IS-10 Historical Marketcap From 2019 to 2026
Between 2019 and today, SOL-GEL TECHN. IS-10's market cap moved from $43.25 Million to $ 250.71 Million, with a yearly change of 32.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €250.71 Million | +73.28% |
| 2025 | €144.69 Million | +3680.00% |
| 2024 | €3.83 Million | -7.41% |
| 2023 | €4.13 Million | -71.88% |
| 2022 | €14.70 Million | -33.22% |
| 2021 | €22.01 Million | -26.28% |
| 2020 | €29.86 Million | -30.97% |
| 2019 | €43.25 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of SOL-GEL TECHN. IS-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $188.25 Million USD |
| MoneyControl | $188.25 Million USD |
| MarketWatch | $188.25 Million USD |
| marketcap.company | $188.25 Million USD |
| Reuters | $188.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more